Jules M. Janssen Daalen

Hypoxic conditioning in Parkinson’s disease: randomized controlled multiple N-of-1 trials Open

Jules M. Janssen Daalen, Marjan J. Meinders, Federica Giardina, Soania Mathur, Philip N. Ainslie , et al. · 2025

Preclinical evidence suggests positive symptomatic and neuroprotective effects of hypoxic conditioning in Parkinson’s disease (PD). This study (NCT05214287) investigated the safety, feasibility, short-term symptomatic and downstream effect…

Exercise and Smoking: Yin and Yang Sharing Protective Power for Parkinson’s? Open

Jules M. Janssen Daalen, Sabine Schootemeijer, Thomas H. Oosterhof, Jilke M. Ripping, Bastiaan R. Bloem , et al. · 2025

Compelling epidemiological evidence suggests that exercise and smoking are modifiable risk factors that are linked to a reduced risk of Parkinson’s disease, possibly because they both exert protective effects on neurodegeneration. Like Yin…

Gait and balance worsening after bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson’s disease: a systematic review Open

Jules M. Janssen Daalen, Ashok K. Selvaraj, Hisse Arnts, Bastiaan R. Bloem, Ronald Bartels , et al. · 2025

Background Deep brain stimulation of the subthalamic nucleus (STN-DBS) is a widely applied therapy in Parkinson’s disease (PD). Occasionally, postoperative worsening of gait or balance occurs, even in the face of a persistently gratifying …

Motor Symptom Variability in Parkinson's Disease: Implications for Personalized Trial Outcomes? Open

Jules M. Janssen Daalen, Maudy van der Heiden, Marjan J. Meinders, Bart Post · 2025

Background The Movement Disorders Society Unified Parkinson Disease Rating Scale (MDS‐UPDRS), Part III, is the gold standard for assessing motor symptoms in Parkinson's disease (PD). However, motor symptoms fluctuate significantly from day…

Respiratory Dysfunction and Abnormal Hypoxic Ventilatory Response in Mild to Moderate Parkinson's Disease Open

Jules M. Janssen Daalen, Isabel R. Straatsma, Jeroen W.H. van Hees, Auke Weevers, Veerle A. van de Wetering‐van Dongen , et al. · 2024

Background Respiratory dysfunction is an important contributor to morbidity and mortality in advanced Parkinson's disease (PD), but it is unclear what parameters are sensitive to diagnose and monitor respiratory dysfunction across disease …

Digital biomarkers for non-motor symptoms in Parkinson’s disease: the state of the art Open

Jules M. Janssen Daalen, Robin van den Bergh, Eva M. Prins, Mahshid Sadat Chenarani Moghadam, Rudie van den Heuvel , et al. · 2024

Digital biomarkers that remotely monitor symptoms have the potential to revolutionize outcome assessments in future disease-modifying trials in Parkinson’s disease (PD), by allowing objective and recurrent measurement of symptoms and signs…

Randomized controlled trial of intermittent hypoxia in Parkinson’s disease: study rationale and protocol Open

Jules M. Janssen Daalen, Marjan J. Meinders, Soania Mathur, Hieronymus W. H. van Hees, Philip N. Ainslie , et al. · 2024

Movement analysis in the diagnosis and management of Parkinson’s disease Open

Johannes Burtscher, Nicolas Bourdillon, Jules M. Janssen Daalen, Aurélien Patoz, Julien F. Bally , et al. · 2024

Contains fulltext : 307597.pdf (Publisher’s version ) (Open Access)

<span>Model‐Informed</span> Precision Dosing Using Machine Learning for Levothyroxine in General Practice: Development, Validation and Clinical Simulation Trial Open

Jules M. Janssen Daalen, Djoeke Doesburg, Liesbeth Hunik, R.L.M. van Kessel, Thomas Herngreen , et al. · 2024

Levothyroxine is one of the most prescribed drugs in the western world. Dosing is challenging due to high‐interindividual differences in effective dosage and the narrow therapeutic window. Model‐informed precision dosing (MIPD) using machi…

How Lifetime Evolution of Parkinson’s Disease Could Shape Clinical Trial Design: A Shared Patient–Clinician Viewpoint Open

Jules M. Janssen Daalen, Aranka Gerritsen, Gijs Gerritse, Jan Gouman, Hannie Meijerink , et al. · 2024

Parkinson’s disease (PD) has a long, heterogeneous, pre-diagnostic phase, during which pathology insidiously accumulates. Increasing evidence suggests that environmental and lifestyle factors in early life contribute to disease risk and pr…

Reply to: Hypoxia treatment of Parkinson’s disease may disrupt the circadian system Open

Jules M. Janssen Daalen, Marjan J. Meinders, Isabel R. Straatsma, Philip N. Ainslie, Dick H. J. Thijssen , et al. · 2023

Case management interventions in chronic disease reduce anxiety and depressive symptoms: A systematic review and meta-analysis Open

Angelika D. Geerlings, Jules M. Janssen Daalen, Jan H. L. Ypinga, Bastiaan R. Bloem, Marjan J. Meinders , et al. · 2023

Background There is no systematic insight into the effect of case management on common complications of chronic diseases, including depressive symptoms and symptoms of anxiety. This is a significant knowledge gap, given that people with a …

How Vacations Affect Parkinson's Disease Open

Jules M. Janssen Daalen, Jessica Hubbers, Mirmohsen Sharifi Bonab, Soania Mathur, Dick H. J. Thijssen , et al. · 2022

Contains fulltext : 290897.pdf (Publisher’s version ) (Open Access)

Lifestyle Interventions for the Prevention of Parkinson Disease Open

Jules M. Janssen Daalen, Sabine Schootemeijer, Edo Richard, Sirwan K.L. Darweesh, Bastiaan R. Bloem · 2022

The prevalence of Parkinson disease (PD) is growing fast, amplifying the quest for disease-modifying therapies in early disease phases where pathology is still limited. Lifestyle interventions offer a promising avenue for preventing progre…

Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: study rationale and protocol Open

Jules M. Janssen Daalen, Marjan J. Meinders, Federica Giardina, Kit C. B. Roes, Bas C. Stunnenberg , et al. · 2022

Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson’s Disease Open

Henricus Berend Speelberg, Jules M. Janssen Daalen, Bastiaan R. Bloem, Jean‐François Gagnon, Bart Post , et al. · 2022

Background: There is growing interest in identifying individuals who are in the prodromal phase of Parkinson’s disease (PD), as these individuals are potentially suitable for inclusion in intervention trials to prevent clinically manifest …

Effectiveness of case management interventions in reducing common and potentially preventable complications associated with Parkinson’s disease:A systematic review and meta-analysis Open

Angelika D. van Halteren, Jules M. Janssen Daalen, Jan H. L. Ypinga, Bastiaan R. Bloem, Marjan J. Meinders , et al. · 2021

Objective We sought to systematically examine the effectiveness of case management interventions on common and potentially preventable complications associated with Parkinson’s disease, both in persons with Parkinson’s disease and in perso…

Determinants of drug prices: a systematic review of comparison studies Open

Jules M. Janssen Daalen, Anouk Den Ambtman, Mark van Houdenhoven, Bart J. F. van den Bemt · 2021

Objective In this systematic review on drug price comparison studies, we report on recent determinants of drug prices in a national and international context to facilitate regulation of drug prices by purchasers and policymakers worldwide.…

Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease Open

Jules M. Janssen Daalen, Anouk Tosserams, Philipp Mahlknecht, Klaus Seppi, Bastiaan R. Bloem , et al. · 2021

The presence of olfactory dysfunction conveys a considerably elevated risk of incident PD, likely more in studies with a higher proportion of women, older individuals or short follow-up duration. Individual patient data are warranted to co…

Jules M. Janssen Daalen YOU? Author Swipe